EA202090082A1 - Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, ее применение и содержащие ее фармацевтические композиции - Google Patents
Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, ее применение и содержащие ее фармацевтические композицииInfo
- Publication number
- EA202090082A1 EA202090082A1 EA202090082A EA202090082A EA202090082A1 EA 202090082 A1 EA202090082 A1 EA 202090082A1 EA 202090082 A EA202090082 A EA 202090082A EA 202090082 A EA202090082 A EA 202090082A EA 202090082 A1 EA202090082 A1 EA 202090082A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mcl
- inhibitor
- combination
- compositions containing
- normous
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000002489 hematologic effect Effects 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 229960000684 cytarabine Drugs 0.000 abstract 1
- 229940075628 hypomethylating agent Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Комбинация, которая содержит ингибитор Mcl-1 и второй противораковый агент, где второй противораковый агент выбран из антрациклинов, цитарабина и гипометилирующих агентов, а также содержащие её композиции и её применение.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523389P | 2017-06-22 | 2017-06-22 | |
| EP17189550 | 2017-09-06 | ||
| PCT/EP2018/066551 WO2018234433A1 (en) | 2017-06-22 | 2018-06-21 | COMBINATION OF MCL-1 INHIBITOR AND CARE TREATMENT STANDARD FOR HEMATOLOGICAL CANCERS, USES AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090082A1 true EA202090082A1 (ru) | 2020-05-22 |
Family
ID=62631122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090082A EA202090082A1 (ru) | 2017-06-22 | 2018-06-21 | Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, ее применение и содержащие ее фармацевтические композиции |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11466023B2 (ru) |
| EP (1) | EP3641775B1 (ru) |
| JP (1) | JP7186731B2 (ru) |
| KR (1) | KR20200018681A (ru) |
| CN (2) | CN111032050B (ru) |
| AR (1) | AR112202A1 (ru) |
| AU (1) | AU2018288520B2 (ru) |
| BR (1) | BR112019026959A2 (ru) |
| CA (1) | CA3068096C (ru) |
| CL (1) | CL2019003763A1 (ru) |
| CO (1) | CO2019014479A2 (ru) |
| CU (1) | CU20190105A7 (ru) |
| EA (1) | EA202090082A1 (ru) |
| ES (1) | ES2971466T3 (ru) |
| GE (1) | GEP20227357B (ru) |
| IL (1) | IL271475B2 (ru) |
| JO (1) | JOP20190287A1 (ru) |
| MA (1) | MA49444A (ru) |
| NI (1) | NI201900128A (ru) |
| PH (1) | PH12019502789A1 (ru) |
| SG (1) | SG11201911891WA (ru) |
| TW (1) | TWI753178B (ru) |
| UA (1) | UA126920C2 (ru) |
| UY (1) | UY37777A (ru) |
| WO (1) | WO2018234433A1 (ru) |
| ZA (1) | ZA201908446B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11957693B2 (en) | 2021-06-11 | 2024-04-16 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-cancer agents |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006508119A (ja) | 2002-11-06 | 2006-03-09 | ワイス | 急性白血病および骨髄異形成症候群の治療のための組み合わせ療法 |
| EP3549951A3 (en) | 2008-12-09 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
| WO2011130689A1 (en) * | 2010-04-15 | 2011-10-20 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
| CA2712747A1 (en) * | 2010-08-11 | 2012-02-11 | Universite De Montreal | Combinatory cancer treatment |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2952213A1 (en) * | 2014-06-13 | 2015-12-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| FR3037956B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037958B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20190062428A1 (en) * | 2017-06-19 | 2019-02-28 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
-
2018
- 2018-06-21 GE GEAP201815242A patent/GEP20227357B/en unknown
- 2018-06-21 EA EA202090082A patent/EA202090082A1/ru unknown
- 2018-06-21 TW TW107121294A patent/TWI753178B/zh active
- 2018-06-21 AU AU2018288520A patent/AU2018288520B2/en active Active
- 2018-06-21 CN CN201880053619.5A patent/CN111032050B/zh active Active
- 2018-06-21 UA UAA202000317A patent/UA126920C2/uk unknown
- 2018-06-21 JP JP2019570386A patent/JP7186731B2/ja active Active
- 2018-06-21 KR KR1020207001915A patent/KR20200018681A/ko not_active Application Discontinuation
- 2018-06-21 IL IL271475A patent/IL271475B2/en unknown
- 2018-06-21 US US16/622,967 patent/US11466023B2/en active Active
- 2018-06-21 WO PCT/EP2018/066551 patent/WO2018234433A1/en unknown
- 2018-06-21 SG SG11201911891WA patent/SG11201911891WA/en unknown
- 2018-06-21 EP EP18731845.6A patent/EP3641775B1/en active Active
- 2018-06-21 ES ES18731845T patent/ES2971466T3/es active Active
- 2018-06-21 CN CN202410099418.6A patent/CN117959451A/zh active Pending
- 2018-06-21 CU CU2019000105A patent/CU20190105A7/es unknown
- 2018-06-21 BR BR112019026959-2A patent/BR112019026959A2/pt unknown
- 2018-06-21 UY UY0001037777A patent/UY37777A/es unknown
- 2018-06-21 MA MA049444A patent/MA49444A/fr unknown
- 2018-06-21 CA CA3068096A patent/CA3068096C/en active Active
- 2018-06-21 AR ARP180101729 patent/AR112202A1/es unknown
- 2018-12-22 JO JOP/2019/0287A patent/JOP20190287A1/ar unknown
-
2019
- 2019-12-10 PH PH12019502789A patent/PH12019502789A1/en unknown
- 2019-12-18 ZA ZA2019/08446A patent/ZA201908446B/en unknown
- 2019-12-19 CL CL2019003763A patent/CL2019003763A1/es unknown
- 2019-12-19 NI NI201900128A patent/NI201900128A/es unknown
- 2019-12-20 CO CONC2019/0014479A patent/CO2019014479A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000934A1 (es) | Agente terapéutico que induce citotoxicidad (divisional de la solicitud no. 201700704) | |
| EA202091491A1 (ru) | Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1 | |
| MX2020006150A (es) | Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas. | |
| SV2018005778A (es) | Derivados aromaticos de sulfonamida | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| MX2021000965A (es) | Composiciones que comprenden polirribonucleotidos circulares y usos de estas. | |
| CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
| CL2018002699A1 (es) | Profármacos de fármacos citotóxicos que tienen grupos enzimáticamente escindibles. | |
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
| EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение | |
| UY37560A (es) | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta | |
| UY37342A (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos | |
| EA202191358A1 (ru) | Новые соединения и их применение в лечении | |
| EA202090082A1 (ru) | Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, ее применение и содержащие ее фармацевтические композиции | |
| EA202191378A1 (ru) | Активные сложноэфирные производные тестостерона, их композиции и применения | |
| GEP20217301B (en) | Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof | |
| NZ756307A (en) | Formulations of cannabinoids for the treatment of acne | |
| MX2019010218A (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| CO2019007261A2 (es) | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta | |
| EA202190766A1 (ru) | Иммуномодуляторы, их композиции и способы применения | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
| CO2018011420A2 (es) | Formulaciones líquidas de fosfaplatino | |
| EA201891680A1 (ru) | Производные индана в качестве модуляторов mglur7 | |
| BR112017022340A2 (pt) | 2-tiopirimidinonas |